This report studies the Hepatocyte Growth Factor market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Hepatocyte Growth Factor market by product type and applications/end industries. Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing. For developing product, there are 3 products in Phase 3, 7 products in Phase 2, 3 products in Phase 1 and 2 products in Preclinical. The total investment for hepatocyte growth factor developing is around 42 M USD in 2017. The major players in global Hepatocyte Growth Factor market include ViroMed AnGes MG M3 Biotechnology AVEO Pharmaceuticals Molecular Partners Yooyoung Pharm F-star Galaxy Biotech Kringle Pharma Geographically, this report is segmented into several key regions, with market size and R&D investment, market share and growth rate of hepatocyte growth factor in these regions, from 2013 to 2030 (forecast), covering North America Europe Asia Pacific RoW On the basis on the end users/applications, this report covers Oncology Cardiovascular Central Nervous System Hematological Disorders Others
Table of Contents 1 Hepatocyte Growth Factor Market Overview 1 1.1 Hepatocyte Growth Factor Product Overview 1 1.2 Hepatocyte Growth Factor Segment by Pipeline 2 1.3 Hepatocyte Growth Factor Segment by Application 3 1.3.1 Global Hepatocyte Growth Factor R&D Investment and Growth Rate Comparison by Application (2013-2023) 3 1.3.2 Global Hepatocyte Growth Factor R&D Investment Market Share b
